{
    "id": 19804,
    "fullName": "HHAT positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "HHAT positive indicates the presence of the HHAT gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 55733,
        "geneSymbol": "HHAT",
        "terms": [
            "HHAT",
            "MART2",
            "SKI1",
            "Skn"
        ]
    },
    "variant": "positive",
    "createDate": "03/15/2016",
    "updateDate": "01/21/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5056,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-SKI 43 inhibited proliferation of breast cancer cells positive for ESR1 and HHAT in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20218,
                "profileName": "ESR1 pos HHAT pos"
            },
            "therapy": {
                "id": 3744,
                "therapyName": "RU-SKI 43",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5060,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-SKI 43 worked synergistically with LY294002 to inhibit proliferation of ESR1- and HHAT-positive breast cancer cells in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20218,
                "profileName": "ESR1 pos HHAT pos"
            },
            "therapy": {
                "id": 3746,
                "therapyName": "LY294002 + RU-SKI 43",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5061,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-SKI 43 worked synergistically with Rapamune (sirolimus) to inhibit proliferation of ER- and HHAT-positive breast cancer cells in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20218,
                "profileName": "ESR1 pos HHAT pos"
            },
            "therapy": {
                "id": 3747,
                "therapyName": "RU-SKI 43 + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5063,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-SKI 43 worked synergistically with Nolvadex (tamoxifen) to inhibit proliferation of ER- and HHAT-positive breast cancer cells in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20218,
                "profileName": "ESR1 pos HHAT pos"
            },
            "therapy": {
                "id": 3748,
                "therapyName": "RU-SKI 43 + Tamoxifen",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5057,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, triple-receptor negative breast cancer cell lines positive for Hhat demonstrated resistance to RU-SKI 43 treatment in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20222,
                "profileName": "ERBB2 neg ESR1 neg HHAT pos PGR neg"
            },
            "therapy": {
                "id": 3744,
                "therapyName": "RU-SKI 43",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5058,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-SKI 43 inhibited proliferation of ER-negative, ERBB2 amplified breast cancer cells positive for HHAT in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20228,
                "profileName": "ERBB2 amp ESR1 neg HHAT pos"
            },
            "therapy": {
                "id": 3744,
                "therapyName": "RU-SKI 43",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5059,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RU-SKI 43 worked synergistically with Tykerb (lapatinib) to inhibit proliferation of ERBB2 (HER2) amplified breast cancer cells positive for HHAT in culture (PMID: 25889650).",
            "molecularProfile": {
                "id": 20230,
                "profileName": "ERBB2 amp HHAT pos"
            },
            "therapy": {
                "id": 3745,
                "therapyName": "Lapatinib + RU-SKI 43",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4868,
                    "pubMedId": 25889650,
                    "title": "Hedgehog Acyltransferase as a target in estrogen receptor positive, HER2 amplified, and tamoxifen resistant breast cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25889650"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 20216,
            "profileName": "HHAT positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20218,
            "profileName": "ESR1 pos HHAT pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20222,
            "profileName": "ERBB2 neg ESR1 neg HHAT pos PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20228,
            "profileName": "ERBB2 amp ESR1 neg HHAT pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 20230,
            "profileName": "ERBB2 amp HHAT pos",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}